Engineered immune cells take aim at childhood leukemia
NCT ID NCT02650414
First seen Jan 07, 2026 · Last updated May 17, 2026 · Updated 15 times
Summary
This study tests a single dose of specially engineered immune cells (CAR T-cells) in children and young adults with B-cell leukemia that has come back or not responded to standard treatments. The cells are designed to target a protein called CD22 on leukemia cells. The main goal is to see if this approach is safe and possible, and to monitor side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.